Precision medicine in lymphoid malignancies

Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about the concept of precision medicine in lymphoid malignancies. He discusses a study presented at the American Society of Hematology (ASH) 2015 Annual Meeting, looking at key mutations in the B-cell receptor (BCR) signaling cascade within diffuse large B-cell lymphoma (DLBCL). The study revealed that certain mutations were associated with a better response to certain drugs, such as ibrutinib. These findings are important as we strive to improve precision in medicine and ensure patients are receiving the best treatment for their disease type.

Share this video